Prediction the results of ablative treatment in patients with uveal melanoma using molecular markers of lymphocyte activation
DOI:
https://doi.org/10.31288/oftalmolzh201524448Keywords:
uveal melanoma, molecular markers of lymphocyte activation, prediction result of treatmentAbstract
Abstract. One approach to predicting the outcome of ablative treatment is the study of the expression of molecular markers of lymphocyte activation. Changing the level of expression of receptors on the cell surface reflects the processes in the body. The purpose — to explore the possibility of predicting the results of ablative treatment using molecular markers of lymphocyte activation.
A comparative analysis of the expression of lymphocyte activation molecular markers was made in 150 patients with uveal melanoma. The expression level of molecular markers of lymphocyte activation CD54+ and CD95+ was studied using monoclonal antibodies by histoimunocytochemical method on peripheral blood lymphocytes. I group (116 patients) — patients with uveal melanoma regression after photocoagulation and ?-therapy; II group (34 patients) — patients with progressive tumor growth and subsequent removal of the eye.
The study evaluated informative predictability of lymphocyte activation molecular markers CD54+ and CD95+ to assess possible to determine the level of markers for predicting success of ablative treatment. ROC-analysis (Receiver Operating Characteristic analysis) showed that molecular markers of lymphocyte activation CD54+ and CD95+ were the most informative. Thresholds expression level was defined on peripheral blood lymphocytes CD54+ (above 171 cells/ml — absolute level) and CD95+ (above 282 cells/ml — absolute level); CD54+ (above 19% — relative level) and CD95+ (above 18% — relative level), predicts regression of melanoma in 77,2% of cases. Expression lymphocyte activathion molecular markers CD54+ and CD95+ below this level allows to predict subsequent tumor growth in 70,5% of cases.
References
Berezhnaia NM. The role of immune system cells in the tumor microenvironment. II. The interaction of cells of the immune system with the other components of the microenvironment. Onkologiia. 2009;11(2):86-93/ In Russian.
Gluzman DF, Sklyarenko LM, Nadgornaia VA, Kryachok IA. Diagnostic immunocytochemistry of tumors. Kiev:Morion; 2003. 6-15.
Kozlov IG, Gorlina NK, Cheredyeyeva AN. Receptors of contact interaction. Immunologiia. 1995;4:14-26. In Russian.
Blank C, Kuball J, Voelkl S et al. Blockade of PD - L1 (B7 - H1) augments human tumor-specific T cell responses in vitro. Int. J. Cancer. 2006;119(2):317-27. https://doi.org/10.1002/ijc.21775
Blom DJ, Luyten GP, Mooy C et al. Human leukocyte antigen class I expression. Marker of poor prognosis in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 1997; 38(9):1865-72.
De Waard-Siebinga I, Hilders CG, Hansen B E. HLA expression and tumor - infiltrating immune cells in uveal melanoma. Arch. Clin. Exp. Ophthalmol. 1996; 234(1):34-42.https://doi.org/10.1007/BF00186516
Fidler IJ, Poste G. The «seed and soil» hypothesis revisited. Lancet Oncol. 2008;9(8):808.https://doi.org/10.1016/S1470-2045(08)70201-8
Fridman WH, Galon J, Pages F et al. Prognostic and predictive impact of intra and peritumoral immune infiltrates. Cancer Res. 2011; 71(17):5601-5.https://doi.org/10.1158/0008-5472.CAN-11-1316
Jameson SC, Bevan MJ. T cell receptor antagonists and partial agonists. Immunity. 1995:2(1):1-11.https://doi.org/10.1016/1074-7613(95)90074-8
Makitie T, Summanen P, Tarkkanen A, Kivela T. Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest. Ophthalmol. Vis. Sci. 2001; 42(7):1414-21.
Mantovani A, Romero P, Palucka AK, Marincola FM. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet. 2008; 371:771-83.https://doi.org/10.1016/S0140-6736(08)60241-X
Shaw A S. Making the T cell receptor go the dis - tance: a topological view of T cell activation / A. S. Shaw, M. L. Dustin // Immunity. - 1997:6. - P. 361-369.https://doi.org/10.1016/S1074-7613(00)80279-4
Singh AD, Shields CL, Shields JA. Prognostic factors in uveal melanoma. Melanoma Res. 2001;11:255-63.https://doi.org/10.1097/00008390-200106000-00007
Vetter CS, Lieb W, Brocker EB, Becker JC. Loss of nonclassical MHC molecules MIC - A/B expression during progression of uveal melanoma. Br. J. Cancer. 2004;91(8):1495-9.https://doi.org/10.1038/sj.bjc.6602123
Wulfing C, Rabinowitz JD, Beeson C et al.. Kinetics and extent of T cell activation as measured with the calcium signal. J. Exp. Med. 1997; 185:1815-25.https://doi.org/10.1084/jem.185.10.1815
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Л. Н. Величко, А. П. Малецкий, В. В. Вит, А. В. Богданова
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.
COPYRIGHT NOTICE
Authors who publish in this journal agree to the following terms:
- Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
- The copyright commencement date complies the publication date of the issue, where the article is included in.
DEPOSIT POLICY
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
- Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
- Archiving the pre-print (pre-refereeing manuscript version) not allowed.
